Hope Care

Hope Care operates a regulated Class IIb medical-device platform inside public health systems at scale, with deployments across 15 Local Health Units covering roughly 45 percent of registered Portuguese NHS users. Published programme results include a 76 percent reduction in hospital days and 74 percent fewer emergency visits in a 12-month COPD cohort.

The company pairs clinical evidence with regulatory maturity across European markets, holding French digital-medical-device conformity certification and expanding operations in France, Germany, and Romania. Its decade-long institutional footprint supports enterprise deployment rather than pilot-stage adoption.

European health systems are shifting chronic care toward remote monitoring and hospital-at-home models as costs and demand rise. France now reimburses remote monitoring through its national health insurance, creating a regulatory pathway for certified platforms operating inside public hospitals.

Certified medical-device platforms with published clinical outcomes stand to benefit as procurement favours regulated, interoperable solutions. Competition remains broad across digital health vendors, but reimbursement-backed deployment rewards regulatory maturity and measured impact.

Hope Care sells OpMA, a regulated remote patient monitoring platform that acts as the digital backbone for telehealth operations centres and hospital-at-home programmes. The platform aggregates medical-device data and patient-reported outcomes into centralised clinical workflows for chronic care.

Healthcare organisations use OpMA to design, deploy, and scale digital care programmes across multiple chronic conditions. The software is certified as a Class IIb medical device under the EU Medical Device Regulation.